P01.05 Deciphering the function of the ubiquitin-proteasome-system in regulating the immune checkpoint protein B7-H3 (CD276) in non-small cell lung cancer

BackgroundCancer cells use the expression of immune checkpoint proteins on their surface to evade immune responses. Targeting these checkpoints with antibodies has substantially advanced cancer therapy in the past years, especially the treatment of lung cancer. However, the prognosis of metastatic l...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer 2021-10, Vol.9 (Suppl 1), p.A5-A5
Main Authors: Kurz, M, Rieger, L, Giansanti, P, Kuster, B, Bassermann, F
Format: Article
Language:English
Subjects:
Cancer therapies
Enzymes
Experiments
Immunotherapy
Lung cancer
Mass spectrometry
Proteins
Scientific imaging
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundCancer cells use the expression of immune checkpoint proteins on their surface to evade immune responses. Targeting these checkpoints with antibodies has substantially advanced cancer therapy in the past years, especially the treatment of lung cancer. However, the prognosis of metastatic lung cancer patients still remains poor and lung cancer remains to be the leading cause of cancer death worldwide. Further therapeutic concepts are therefore urgently needed.It has been shown that protein expression levels of the immune checkpoint protein PD-L1, a member of the B7 protein family, is regulated by the ubiquitin-proteasome system (UPS). Ubiquitin-ligases (E3-ligases) and deubiquitinating enzymes that regulate immune checkpoint levels on the cell surface are therefore considered promising potential drug targets. Inhibiting enzymes that increase immune checkpoint surface levels might increase the anti-cancer immune response.Here, we investigate whether another B7 family member, immune checkpoint protein B7-H3, is regulated by the UPS in non-small cell lung cancer (NSCLC).Materials and MethodsB7-H3 expression in NSCLC cell lines and patient samples was evaluated using mRNASeq data from open databases. Immunoblotting and FACS were used to analyse total endogenous protein levels and surface expression of B7-H3 in different NSCLC lines under normal growth conditions and in response to various inhibitors (MG-132, Chloroquine (CQ) and Cycloheximide (CHX)). Immunoprecipitation of FLAG-tagged B7-H3 followed by a TUBE IP using ubiquitin-binding beads and in-vivo ubiquitylation assays based on co-overexpression of HA-tagged ubiquitin and/or HA-tagged K48/K63-linkages specific ubiquitin together with FLAG-tagged B7-H3 or FLAG-tagged B7-H3 K526R mutant in HEK-93T cells were performed to analyse ubiquitination on B7-H3. Mass spectrometry analysis of FLAG-purified B7-H3 was performed to identify possible interaction partners.ResultsDatabase analysis revealed that B7-H3 expression is higher in lung cancer samples than in healthy lung tissue. We found that B7-H3 is highly expressed in different NSCLC lines on RNA and protein levels. Treatments with either proteasomal (MG-132) or lysosomal (CQ) degradation inhibitors alone showed only minor effects on B7-H3 protein abundance. However, CHX treatment of H1437 cells decreased B7-H3 over time and this decrease was recovered by adding MG-132 or CQ suggesting that both the lysosome as well as proteasome are involved in the
ISSN:2051-1426
DOI:10.1136/jitc-2021-ITOC8.9